These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 32642740)

  • 1. Quality of life in patients with neurofibromatosis type 1 and 2 in Canada.
    Hamoy-Jimenez G; Kim R; Suppiah S; Zadeh G; Bril V; Barnett C
    Neurooncol Adv; 2020 Jul; 2(Suppl 1):i141-i149. PubMed ID: 32642740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A cross-sectional study of gender differences in quality of life domains in patients with neurofibromatosis type 1.
    Hamoy-Jimenez G; Elahmar HA; Mendoza M; Kim RH; Bril V; Barnett C
    Orphanet J Rare Dis; 2022 Feb; 17(1):40. PubMed ID: 35135568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of neurofibromatosis type 1 with plexiform neurofibromas on the health-related quality of life and work productivity of adult patients and caregivers in the UK: a cross-sectional survey.
    Yoo HK; Porteous A; Ng A; Haria K; Griffiths A; Lloyd A; Yang X; Kazeem G; Barut V
    BMC Neurol; 2023 Nov; 23(1):419. PubMed ID: 37996843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health-related quality of life in patients with neurofibromatosis 1 in Japan: A questionnaire survey using EQ-5D-5L.
    Yoshida Y; Ehara Y; Koga M; Imafuku S
    J Dermatol; 2022 Dec; 49(12):1228-1232. PubMed ID: 35781730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between whole-body tumor burden, clinical phenotype, and quality of life in patients with neurofibromatosis.
    Merker VL; Bredella MA; Cai W; Kassarjian A; Harris GJ; Muzikansky A; Nguyen R; Mautner VF; Plotkin SR
    Am J Med Genet A; 2014 Jun; 164A(6):1431-7. PubMed ID: 24664633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The NFTI-QOL: A Disease-Specific Quality of Life Questionnaire for Neurofibromatosis 2.
    Hornigold RE; Golding JF; Leschziner G; Obholzer R; Gleeson MJ; Thomas N; Walsh D; Saeed S; Ferner RE
    J Neurol Surg B Skull Base; 2012 Apr; 73(2):104-11. PubMed ID: 23543835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The German version of the neurofibromatosis 2 impact on quality of life questionnaire correlates with severity of depression and physician-reported disease severity.
    Lawson McLean AC; Freier A; Lawson McLean A; Kruse J; Rosahl S
    Orphanet J Rare Dis; 2023 Jan; 18(1):3. PubMed ID: 36604703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Construct validity of patient-reported outcome instruments in US adults with hemophilia: results from the Pain, Functional Impairment, and Quality of life (P-FiQ) study.
    Batt K; Recht M; Cooper DL; Iyer NN; Kempton CL
    Patient Prefer Adherence; 2017; 11():1369-1380. PubMed ID: 28860720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measuring health-related quality of life in chronic obstructive pulmonary disease: properties of the EQ-5D-5L and PROMIS-43 short form.
    Lin FJ; Pickard AS; Krishnan JA; Joo MJ; Au DH; Carson SS; Gillespie S; Henderson AG; Lindenauer PK; McBurnie MA; Mularski RA; Naureckas ET; Vollmer WM; Lee TA;
    BMC Med Res Methodol; 2014 Jun; 14():78. PubMed ID: 24934150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential Psychometric Properties of EuroQoL 5-Dimension 5-Level and Short-Form 6-Dimension Utility Measures in Low Back Pain.
    Cheung PWH; Wong CKH; Cheung JPY
    Spine (Phila Pa 1976); 2019 Jun; 44(11):E679-E686. PubMed ID: 30475342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Do Cohabitants Reliably Complete Questionnaires for Patients in a Terminal Cancer Stage when Assessing Quality of Life, Pain, Depression, and Anxiety?
    Groot OQ; Paulino Pereira NR; Bongers MER; Ogink PT; Newman ET; Verlaan JJ; Raskin KA; Lozano-Calderon SA; Schwab JH
    Clin Orthop Relat Res; 2021 Apr; 479(4):792-801. PubMed ID: 33165035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Direct Comparison of the Measurement Properties of EQ-5D-5L, PROMIS-29+2 and PROMIS Global Health Instruments and EQ-5D-5L and PROPr Utilities in a General Population Sample.
    Rencz F; Brodszky V; Janssen MF
    Value Health; 2023 Jul; 26(7):1045-1056. PubMed ID: 36804583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EQ-5D-5L and SF-6Dv2 utility scores in people living with chronic low back pain: a survey from Quebec.
    Poder TG; Wang L; Carrier N
    BMJ Open; 2020 Sep; 10(9):e035722. PubMed ID: 32933957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cognitive functioning and pain interference mediate pain predictive effects on health-related quality of life in pediatric patients with Neurofibromatosis Type 1.
    Varni JW; Nutakki K; Swigonski NL
    Eur J Paediatr Neurol; 2020 Sep; 28():64-69. PubMed ID: 32847704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current Recommendations for Patient-Reported Outcome Measures Assessing Domains of Quality of Life in Neurofibromatosis Clinical Trials.
    Wolters PL; Vranceanu AM; Thompson HL; Martin S; Merker VL; Baldwin A; Barnett C; Koetsier KS; Hingtgen CM; Funes CJ; Tonsgard JH; Schorry EK; Allen T; Smith T; Franklin B; Reeve S;
    Neurology; 2021 Aug; 97(7 Suppl 1):S50-S63. PubMed ID: 34230198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Measurement properties of the EQ-5D-5L and PROPr in patients with spinal muscular atrophy.
    Xu RH; Ma B; Xin H; Zhang H; Zeng Y; Luo N; Dong D
    Health Qual Life Outcomes; 2023 Nov; 21(1):123. PubMed ID: 37968716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EQ-5D-5L and SF-6D Utility Measures in Symptomatic benign Thyroid Nodules: Acceptability and Psychometric Evaluation.
    Wong CKH; Lang BHH; Yu HMS; Lam CLK
    Patient; 2017 Aug; 10(4):447-454. PubMed ID: 28224296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health utility reporting in chronic rhinosinusitis patients.
    Bewick J; Morris S; Hopkins C; Erskine S; Philpott CM
    Clin Otolaryngol; 2018 Feb; 43(1):90-95. PubMed ID: 28498517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Baseline characteristics of adults with neurofibromatosis enrolled on a psychosocial randomized controlled trial.
    Fishbein NS; Vranceanu AM; Mace RA
    J Neurooncol; 2022 Sep; 159(3):637-646. PubMed ID: 35925531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Appearance concerns among women with neurofibromatosis: examining sexual/bodily and social self-consciousness.
    Smith KB; Wang DL; Plotkin SR; Park ER
    Psychooncology; 2013 Dec; 22(12):2711-9. PubMed ID: 23873824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.